跳至主要内容
临床试验/IRCT20190210042676N29
IRCT20190210042676N29招募中2 期

Evaluation of safety and effectiveness of an injectable solution containing deoxycholic acid with the brand name ®Embella, in order to reduce submental fat.

Zist orchid pharmed Company0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 65 years(—)
性别
All

入选标准

  • Ages 18 to 65
  • People with unwanted submental fat with moderate to severe intensity, grades 2 and 3 of the clinical grade of SMF (submental fat) evaluation
  • Have signed the informed consent form and agree to a 3-month follow-up.

排除标准

  • Any previous intervention to treat submental fat.
  • Specific anatomical features or previous damage to the intervention site (ulcers, liposuction, difficulty swallowing, enlargement of the thyroid gland or lymph nodes) that interfere with the evaluation of intervention results.
  • History of dysphagia

研究者

发起方
Zist orchid pharmed Company

相似试验